Related Experiment Video
Updated: Aug 25, 2025
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles
Armita Mahdavi Gorabi1, Mehrnaz Sadat Ravari2, Mohammad-Javad Sanaei3
1Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Abstract:
The early stages of melanoma could be treated promisingly by surgical resection; however, the challenge is in advanced cases in which targeted therapy could be an option. The expression of immune checkpoints such as CTLA-4, PD-1, PD-L1, TIM-3, LAG-3, and VISTA is at adequate levels in the melanoma tumor microenvironment (TME) implying the promising outcomes of applying immune checkpoint blockades (ICBs). Since the first Food and Drug Administration (FDA) approved ICB, ipilimumab, in melanoma patients, the treatment of melanoma patients with ICBs resulted in improved survival rate and anti-tumor responses, making ICB one of the promising therapeutic approaches. However, due to high biodistribution, these drugs could non-specifically target healthy cells and empower the immune reactions out of control, which results in the incidence of immune-related adverse events. Although there are development management approaches, a new emerging platform is recently available with aid of drug delivery strategies, particularly nanoparticles (NPs). Here, we investigated the recent trials of ICBs in the context of melanoma cases while showing the challenges of this approach. Also, the application of NPs in order to locally deliver ICBs in melanoma tumor models is discussed.
Insights
Immune checkpoint blockades (ICBs) show promise for advanced melanoma, but can cause side effects. Nanoparticles offer a new strategy for targeted ICB delivery to improve melanoma treatment outcomes.
Area of Science:
- Oncology
- Immunology
- Nanotechnology
Background:
- Advanced melanoma presents treatment challenges beyond surgical resection.
- Immune checkpoints (e.g., CTLA-4, PD-1) are expressed in the melanoma tumor microenvironment (TME), making immune checkpoint blockades (ICBs) a promising therapeutic strategy.
- ICBs have improved survival rates and anti-tumor responses in melanoma patients, but systemic administration can lead to immune-related adverse events due to non-specific targeting.
Purpose of the Study:
- To review recent trials of ICBs in melanoma.
- To highlight the challenges associated with current ICB therapies.
- To explore the potential of nanoparticles (NPs) for localized ICB delivery in melanoma models.
Main Methods:
- Review of recent clinical trials involving ICBs for melanoma.
- Analysis of the challenges and limitations of systemic ICB administration.
- Discussion of nanoparticle-based drug delivery strategies for localized ICB therapy.
Main Results:
- ICBs have demonstrated efficacy in improving outcomes for melanoma patients.
- Systemic delivery of ICBs can result in off-target effects and immune-related adverse events.
- Nanoparticle-based drug delivery presents a potential solution for localized and targeted ICB administration.
Conclusions:
- ICBs are a significant advancement in melanoma treatment, but managing adverse events remains crucial.
- Nanoparticle technology offers a promising platform to enhance the safety and efficacy of ICBs by enabling targeted delivery.
- Further research into NP-mediated ICB delivery could revolutionize melanoma therapy.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...